Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial
Stroke · 2026
DOI: 10.1161/strokeaha.124.050418 ↗At a glance
Randomisierte kontrollierte Studie in Stroke, 2026. Written by Ashkan Shoamanesh and 21 co-authors. Institution: Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (A.S., S.J.C., L.X., M.C., M.S.). Major MEDLINE topics: Hematoma, Cerebral Hemorrhage, Factor Xa Inhibitors, Factor Xa. Cited 3 times so far (Crossref); 18 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
BACKGROUND: Andexanet improves hemostatic efficacy in FXa (factor Xa) inhibitor–associated intracranial hemorrhage but carries a risk of thrombotic events. These secondary analyses of the ANNEXA-I trial (A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor) examined determinants of hematoma expansion (HE) and the corresponding response to andexanet. METHODS: ANNEXA-I enrolled patients aged ≥18 years with acute FXa inhibitor–associated intracranial hemorrhage within 6 hours of onset between June 6, 2019, and May 27, 2023, at 131 sites in 23 countries. Participants were randomized (1:1) to andexanet or usual care. Among 530 participants, 459 (87%) had a qualifying intracerebral hemorrhage and adequate brain imaging for these analyses. The primary outcome was HE (≥12.5-mL or ≥35% increase in baseline volume) at 12 hours. We report differences in the proportion of HE between treatment groups stratified by variables significantly associated with HE in regression models. RESULTS: HE occurred in 149 of 459 participants (32.5%). Symptom onset-to-treatment time (adjusted odds ratio per hour, 0.73 [95% CI, 0.63–0.85]), baseline hematoma volume (adjusted odds ratio per 10 mL, 1.11 [95% CI, 1.01–1.23]), and diastolic blood pressure (adjusted odds ratio per 10 mm Hg, 1.15 [95% CI, 1.02–1.29]) were associated with HE but not thrombotic events. In a separate multivariable model replacing volume and onset-to-treatment time with prescan hematoma growth rate, growth rate was also associated with HE (adjusted odds ratio per mL/h, 1.02 [95% CI, 1.01–1.04]). Patients in the highest risk quartiles (baseline volume >22.4 mL, growth rate >11.4 mL/h, diastolic blood pressure >95.0 mm Hg, and onset-to-treatment time ≤3.3 hours) had ≈50% to 60% absolute risk of HE with usual care. Numerically greater absolute risk reductions with andexanet (≈25%; number needed to treat: 4) were observed in the highest quartiles of baseline volume and growth rate. CONCLUSIONS: Shorter onset-to-treatment time, larger baseline hematoma volume, higher diastolic blood pressure, and higher prescan hematoma growth rate predict HE but not thrombotic events in FXa inhibitor–associated intracerebral hemorrhage. Andexanet benefit is observed across these ranges and may be amplified through patient selection using these metrics. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03661528.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (A.S., S.J.C., L.X., M.C., M.S.).
- Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada (A.M.D.).
- Department of Neurology, Inselspital University Hospital and University of Bern, Switzerland (D.J.S.).
- Department of Neurology, Oslo University Hospital and the Norwegian Air Ambulance Foundation, Norway (E.C.S.).
- Department of Neurology, Vall d'Hebron Stroke Center, Autonomous University of Barcelona, Spain (C.A.M.).
- Second Department of Neurology, National and Kapodistrian University of Athens, Attikon University Hospital, Greece (G.T.).
ORCID profiles: Ashkan Shoamanesh, Stuart J Connolly, Andrew M Demchuk, David J Seiffge, Else Charlotte Sandset, Carlos A Molina, Georgios Tsivgoulis, Hanne Christensen, Jan Beyer-Westendorf, Jonathan M Coutinho, Pierre Amarenco, Robin Lemmens, Roland Veltkamp, Saskia Middeldorp, Andrea Zini, Per Ladenvall, Mukul Sharma
Cite
APA
Shoamanesh, A., Connolly, S. J., Demchuk, A. M., Seiffge, D. J., Sandset, E. C., Molina, C. A., Tsivgoulis, G., Christensen, H., Beyer-Westendorf, J., Coutinho, J. M., Amarenco, P., Lemmens, R., Veltkamp, R., Middeldorp, S., Zini, A., Himmelmann, A., Ladenvall, P., Knutsson, M., Xu, L., …, & ANNEXA-I Investigators (2026). Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial. Stroke. https://doi.org/10.1161/strokeaha.124.050418
Vancouver
Shoamanesh A, Connolly SJ, Demchuk AM, Seiffge DJ, Sandset EC, Molina CA, et al. Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial. Stroke. 2026. doi:10.1161/strokeaha.124.050418
BibTeX
@article{Shoamanesh2026,
author = {Shoamanesh, Ashkan and Connolly, Stuart J and Demchuk, Andrew M and Seiffge, David J and Sandset, Else Charlotte and Molina, Carlos A and Tsivgoulis, Georgios and Christensen, Hanne and Beyer-Westendorf, Jan and Coutinho, Jonathan M and Amarenco, Pierre and Lemmens, Robin and Veltkamp, Roland and Middeldorp, Saskia and Zini, Andrea and Himmelmann, Anders and Ladenvall, Per and Knutsson, Mikael and Xu, Lizhen and Crowther, Mark and Sharma, Mukul and ANNEXA-I Investigators, ANNEXA-I Investigators},
title = {Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial},
journal = {Stroke},
year = {2026},
doi = {10.1161/strokeaha.124.050418}
}
EUVIMED